Late-stage cancer treatment approved
A new combination therapy for late-stage cervical cancer has been approved by the FDA. Topotecan (Hycamtin, GlaxoSmithKline) and cisplatin together can now be used for women in stage IV-B with incurable, recurrent, or persistent cancer of the cervix that has spread to other organs and is not likely to respond to surgery or radiation.
Late-stage cancer treatment approved
A new combination therapy for late-stage cervical cancer has been approved by the FDA. Topotecan (Hycamtin, GlaxoSmithKline) and cisplatin together can now be used for women in stage IV-B with incurable, recurrent, or persistent cancer of the cervix that has spread to other organs and is not likely to respond to surgery or radiation. The addition of topotecan improved survival over cisplatin alone by three months (9.4 months vs. 6.5 months) in clinical trials involving 293 patients.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
